| dbo:abstract
|
- Razupenem (PTZ-601) is a broad spectrum injectable antibiotic, from the carbapenem subgroup of beta-lactam antibiotics. It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics. Razupenem performed well against a variety of bacterial strains, but further development is in doubt due to a high rate of side effects in Phase II clinical trials. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 2934 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:h
| |
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:legalUs
|
- Investigational New Drug (en)
|
| dbp:n
| |
| dbp:o
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- XFGOMLIRJYURLQ-GOKYHWASSA-N (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Razupenem (PTZ-601) is a broad spectrum injectable antibiotic, from the carbapenem subgroup of beta-lactam antibiotics. It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics. Razupenem performed well against a variety of bacterial strains, but further development is in doubt due to a high rate of side effects in Phase II clinical trials. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
